Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AMZ2P2 is a retrocopy (processed pseudogene) of the protein-coding gene AMZ2[7]. Pseudogenes typically arise from duplication or reverse transcription events and lack the ability to encode a functional protein[8][9]. AMZ2P2 is catalogued in several genomic databases (HGNC: 38072, NCBI Gene: 100421018), but there is no evidence for translation or therapeutic relevance. Unlike its parent AMZ2, which participates in zinc metallopeptidase activity and is associated with certain diseases, AMZ2P2 itself does not have any documented biological function, disease association, or pharmacological importance[7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Archaelysin family metallopeptidase 2 pseudogene 2 (AMZ2P2).